- Home
- THAR vs CBUS Comparison
THAR vs CBUS Comparison
Compare THAR & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- CBUS
- Stock Information
- Founded
- THAR 2017
- CBUS 2010
- Country
- THAR United States
- CBUS United States
- Employees
- THAR N/A
- CBUS N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- CBUS Agricultural Chemicals
- Sector
- THAR Health Care
- CBUS Industrials
- Exchange
- THAR Nasdaq
- CBUS Nasdaq
- Market Cap
- THAR 85.9M
- CBUS 69.9M
- IPO Year
- THAR 2022
- CBUS 2017
- Fundamental
- Price
- THAR $2.54
- CBUS $1.30
- Analyst Decision
- THAR Strong Buy
- CBUS Strong Buy
- Analyst Count
- THAR 1
- CBUS 2
- Target Price
- THAR $17.00
- CBUS $21.25
- AVG Volume (30 Days)
- THAR 3.5M
- CBUS 170.2K
- Earning Date
- THAR 11-12-2025
- CBUS 11-13-2025
- Dividend Yield
- THAR N/A
- CBUS N/A
- EPS Growth
- THAR N/A
- CBUS N/A
- EPS
- THAR N/A
- CBUS N/A
- Revenue
- THAR N/A
- CBUS $3,794,000.00
- Revenue This Year
- THAR N/A
- CBUS $17.67
- Revenue Next Year
- THAR N/A
- CBUS $63.43
- P/E Ratio
- THAR N/A
- CBUS N/A
- Revenue Growth
- THAR N/A
- CBUS N/A
- 52 Week Low
- THAR $0.95
- CBUS $1.09
- 52 Week High
- THAR $9.08
- CBUS $4.96
- Technical
- Relative Strength Index (RSI)
- THAR 40.23
- CBUS 46.74
- Support Level
- THAR $2.18
- CBUS $1.24
- Resistance Level
- THAR $2.55
- CBUS $1.36
- Average True Range (ATR)
- THAR 0.42
- CBUS 0.10
- MACD
- THAR -0.10
- CBUS -0.00
- Stochastic Oscillator
- THAR 10.34
- CBUS 71.67
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.